IDEXX Laboratories (IDXX) Competitors

IDEXX Laboratories (NASDAQ:IDXX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Which has higher earnings and valuation, IDXX or SYK?

Stryker has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$3.66B	9.38	$845.04M	$10.37	40.43
Stryker	$20.50B	7.14	$3.17B	$9.33	41.15

Does the MarketBeat Community prefer IDXX or SYK?

Stryker received 392 more outperform votes than IDEXX Laboratories when rated by MarketBeat users. However, 72.36% of users gave IDEXX Laboratories an outperform vote while only 64.76% of users gave Stryker an outperform vote.

Company	Underperform	Outperform
IDEXX Laboratories	Outperform Votes 534 72.36%	Underperform Votes 204 27.64%
Stryker	Outperform Votes 926 64.76%	Underperform Votes 504 35.24%

Do institutionals & insiders have more ownership in IDXX or SYK?

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 2.2% of IDEXX Laboratories shares are held by company insiders. Comparatively, 5.5% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, IDXX or SYK?

IDEXX Laboratories has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Does the media prefer IDXX or SYK?

In the previous week, Stryker had 11 more articles in the media than IDEXX Laboratories. MarketBeat recorded 24 mentions for Stryker and 13 mentions for IDEXX Laboratories. Stryker's average media sentiment score of 1.31 beat IDEXX Laboratories' score of 0.82 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	18 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IDXX or SYK more profitable?

IDEXX Laboratories has a net margin of 22.53% compared to Stryker's net margin of 16.34%. IDEXX Laboratories' return on equity of 55.42% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	22.53%	55.42%	25.90%
Stryker	16.34%	23.07%	11.04%

Do analysts rate IDXX or SYK?

IDEXX Laboratories presently has a consensus target price of $523.86, indicating a potential upside of 24.95%. Stryker has a consensus target price of $405.80, indicating a potential upside of 5.70%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe IDEXX Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Stryker	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

IDEXX Laboratories beats Stryker on 11 of the 19 factors compared between the two stocks.